Literature DB >> 10155279

Therapeutic dilemmas. An approach to the management of expensive pharmaceutical advances.

L Y Nishimura1, R Shane.   

Abstract

Mesh:

Year:  1994        PMID: 10155279     DOI: 10.2165/00019053-199406060-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  35 in total

1.  New England Deaconess Hospital reduces lengths of stay and enhances patient satisfaction in a tertiary-care environment.

Authors:  K Southwick
Journal:  Strateg Healthc Excell       Date:  1993-03

2.  Clinical aspects of therapeutic substitution.

Authors:  R A Levy
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

3.  Therapeutic substitution: an option for cost-effective prescribing?

Authors:  S R Shulman; W Gouveia
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

4.  Strategic planning for the management of biotechnologic products: development of a biotech committee.

Authors:  K Akinwande; T Tse; M Darab; A Madura; R Cerceo; A Al-Hani
Journal:  Hosp Formul       Date:  1993-09

5.  Rationing health care: the choice before us.

Authors:  H Aaron; W B Schwartz
Journal:  Science       Date:  1990-01-26       Impact factor: 47.728

6.  Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.

Authors:  A Corbet; R Bucciarelli; S Goldman; M Mammel; D Wold; W Long
Journal:  J Pediatr       Date:  1991-02       Impact factor: 4.406

7.  AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings. American Medical Association.

Authors: 
Journal:  Am J Hosp Pharm       Date:  1994-07-15

8.  Critical path method: an important tool for coordinating clinical care.

Authors:  P A Hofmann
Journal:  Jt Comm J Qual Improv       Date:  1993-07

Review 9.  Strategic antibiotic decision-making at the formulary level.

Authors:  R Quintiliani; C H Nightingale; H M Crowe; B W Cooper; R C Bartlett; G Gousse
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

10.  The internist as gatekeeper. Preparing the general internist for a new role.

Authors:  J M Eisenberg
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

View more
  2 in total

1.  A purchaser perspective of managing new drugs: interferon beta as a case study.

Authors:  T Walley; S Barton
Journal:  BMJ       Date:  1995-09-23

Review 2.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.